Serum Magnesium and C-peptide levels in Iraqi women with polycystic ovary syndrome

Abstract

Magnesium (Mg) is the second most frequent intracellular cation in humans with critical role in insulin metabolism and glucoregulation. It is an antioxidant and acts as a cofactor for several enzymes. Evaluate serum Mg levels Iraqi women with PCOS and assess its relationship with C-peptide and BMI. This is a case control study that included 80 women with PCOS and 80 healthy volunteers (as control group) in the age range between 18-45 years old. C-peptide was measured using ELISA technique, while Mg was measured using a spectrophotometric technique. Serum C-peptide levels were significantly higher in PCOS patients compared to the control group. In PCOS patients, serum magnesium concentration was significantly lower compared to the control group. This experiment found no correlation between Mg, C-peptide, or BMI. The ROC analysis area under the curves for Mg and C-peptide were 0.803 and 0.875, respectively. These figures demonstrate analysis method reliability. PCOS patients had lower blood magnesium and higher C-peptide levels. No statistically significant relationship was found between these factors. Due to the low magnesium levels in PCOS women's serum. The correlation between lower serum magnesium and higher C-peptide levels in PCOS patients was not significant. Lower serum magnesium levels in women with PCOS need further study and treatment to determine its role and association with PCOS.

Keywords

• Magnesium
• C-peptide
• Polycystic Ovary Syndrome
• ELISA

Supporting Institution

This research is supported by Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University and Al-Immamain Al-Kadhmain MedicalCity, Baghdad, Iraq

Ethical Statement

Ethical approval was received from the ethical and research committee of College of Medicine-Al-Nahrain University- Iraq. Informed consent was obtained from all participants.

Thanks

We would like to thank all the women who agreed to participate in this study, also we are most grateful to the laboratory staff and technicians of the Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University and Al-Immamain Al-Kadhmain Medical city for their help in the analysis of the parameters in this study.

References

1. Dumesic DA, Abbott DH, Sanchita S, Chazenbalk GD. Endocrine–metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective. Curr Opin Endocr Metab Res. 2020;12:41-8.
2. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2013;11:56.
3. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2005;30:400-418.
4. Liu S, Navarro G, Mauvais-Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One. 2010;5
5. Hatziagelaki E, Pergialiotis V, Kannenberg JM, Trakakis E, Tsiavou A, Markgraf DF, et al. Association between biomarkers of low-grade inflammation and sex hormones in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2020;128:723-730.
6. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Dauod G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016;7:124.
7. Shenta A, Saud K, Al-Shawi A. Assessment the correlations of hormones, lipid profiles, oxidative stress, and zinc concentration in Iraqi women with polycystic ovary syndrome. Rep Biochem Mol Biol. 2020;9(3):270-277.
8. Forst T, Kunt T, Pfützner A, Beyer J, Wahren J. New aspects on biological activity of C-peptide in IDDM patients. Exp Clin Endocrinol Diabetes. 1998;106:270-276.

9. Becht FS, Walther K, Martin E, Nauck MA. Fasting C-peptide and related parameters characterizing insulin secretory capacity for correctly classifying diabetes type and for predicting insulin requirement in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2016;124:148-156.
10. Cardellini M, Farcomeni A, Ballanti M. C-peptide: A predictor of cardiovascular mortality in subjects with established atherosclerotic disease. Diab Vasc Dis Res. 2017;14:395-399.
11. Cabrera de León A, Oliva García JG, Marcelino Rodríguez I. C-peptide as a risk factor of coronary artery disease in the general population. Diab Vasc Dis Res. 2015;12:199-207.
12. Matthews DR, Rudenski AS, Burnett MA, Darling P, Turner RC. The half-life of endogenous insulin and C-peptide in man assessed by somatostatin suppression. Clin Endocrinol (Oxf). 1985;23:71-79.
13. Khan HA, Sobki SH, Ekhzaimy A, Khan I, Almusawi MA. Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals. Saudi J Biol Sci. 2018;25:1729-1732.
14. Kauffman RP, Tullar PE, Nipp RD, Castracane VD. Serum magnesium concentrations and metabolic variables in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2011;90(5):452-458.
15. Swetha N, Vyshnavi R, Modagan P, Rajagopalan B. A correlative study of biochemical parameters in polycystic ovarian syndrome. Int J Biol Med Res. 2013;4:3148-3154.
16. Chutia H, Lynrah KG. Association of serum magnesium deficiency with insulin resistance in type 2 diabetes mellitus. J Lab Physicians. 2015;7:075-078.
17. Ruxton GD. The unequal variance t-test is an underused alternative to Student’s t-test and the Mann-Whitney U test. Behav Ecol. 2006;17:688-690.
18. Momo AS, Ama Moor VJ, Tankeu AT, Amazia F, Sadeu Wafeu G, Guewo-Fokeng M, et al. Adiponectin levels and its relation with insulin secretion and insulin sensitivity in a group of sub-Saharan African women with polycystic ovary syndrome. BMC Res Notes. 2022;15:24.
19. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome: Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;96:520-527.
20. Babapour M, Mohammadi H, Kazemi M, Hadi A, Rezazadegan M, Askari G. Associations between serum magnesium concentrations and polycystic ovary syndrome status: a systematic review and meta-analysis. Biol Trace Elem Res. 2021;199:1297-1305.
21. Rajeswari G, Veerabhadrudu B, Suresh E. Study of magnesium levels in polycystic ovarian syndrome. Int J Adv Sci Res. 2016;2(02):054-058.
22. Hasan SA, Rasoul NS, Salih SR. In Iraqi polycystic ovarian syndrome (PCOS), women are affected by oxidative stress, antioxidants, and a few biological factors. Eurasian Med Res Periodical. 2022;9:21-25.
23. Farsinejad-Marj M, Azadbakht L, Mardanian F, Saneei P, Esmaillzadeh A. Clinical and metabolic responses to magnesium supplementation in women with polycystic ovary syndrome. Biol Trace Elem Res. 2020. https://doi.org/10.1007/s12011-019-01923-z.
24. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
25. Dahan MH, Reaven G. Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome. Endocrine. 2019;64:685-689.
26. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000;15(6):1266-1274.
27. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab. 1998;83(11):3984-3991.